TB or not TB: Update from the ERS respiratory infection assembly 10

European Respiratory Journal

Volumn 36, Issue 3, 2010, Pages 665-670

  Miravitlles, M ^a   Ferrara, G ^b   Lange, C ^e   Dimopoulos, G ^f   Rohde, G ^g   Blasi, F ^c   Migliori, G B ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e RESEARCH CENTER BORSTEL   (Germany)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

European Respiratory Society Congress; Respiratory infections; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOSUPPRESSIVE AGENT; PRO ATRIAL NATRIURETIC PEPTIDE; PRO VASOPRESSIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASOPRESSIN;

ANTIBIOTIC THERAPY; ARTERIAL CARBON DIOXIDE TENSION; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BRONCHOSCOPY; CHILDHOOD DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DIAGNOSTIC TEST; DISEASE EXACERBATION; DISEASE SEVERITY; EUROPE; HAEMOPHILUS INFLUENZAE; HEALTH CARE PERSONNEL; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; LOWER RESPIRATORY TRACT INFECTION; LUNG TUBERCULOSIS; MEDICAL SOCIETY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TILBURGII; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM XENOPEI; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; REVIEW; SPUTUM ANALYSIS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EUROPE; HUMANS; INTERNATIONAL COOPERATION; PROGNOSIS; PULMONARY MEDICINE; RESPIRATORY TRACT INFECTIONS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77956603064     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00054410     Document Type: Review

References (58)

1. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180.
2. World Health Organization, Global Tuberculosis Control 2009: Epidemiology. Strategy. Financing: WHO Report 2009. Geneva, World Health Organization, 2009.
3. World Health Organization, Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva, World Health Organization, 2010.
4. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
5. Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe. Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe. www.gracelrti.org Date last updated: April 8, 2010. Date last accessed: April 8, 2010.
6. TB PAN-NET. European Network for Study and Clinical Management of TB Drug Resistance. www.tbpannet.eu Date last updated: April 8, 2010. Date last accessed: April 8, 2010.
7. Sotgiu G, Centis R, D'Ambrosio L, et al. Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. Eur Respir J 2010; 36: 208-211.
8. Ewig S, Soler N, Gonzalez J, et al. Evaluation of antimicrobial treatment in mechanically ventilated patients with severe chronic obstructive pulmonary disease exacerbations. Crit Care Med 2000; 28: 692-697.
9. Jiang H, Li Z. Effect of biofilm on induced b-lactamase production in Pseudomonas aeruginosa with different genotype. Eur Respir J 2009; 34: Suppl. 53, 231s.
10. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542-1548.
11. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40-46.
12. Lode H, Allewelt M, Balk S, et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35: 143-149.
13. Monsó E, García-Aymerich J, Soler N, et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect 2003; 131: 799-804.
14. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-1505.
15. Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 853-860.
16. O'Donnell A, Swarnakar R, Yashina L, et al. A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic Pseudomonas aeruginosa lung infection. Eur Respir J 2009; 34: Suppl. 53, 231s.
17. Bilton D, DeSoyza A, Haworth C, et al. Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in non-CF bronchiectasis. Eur Respir J 2009; 34: Suppl. 53, 231s.
18. Christ-Crain M, Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007; 30: 556-573.
19. Stolz D, Christ-Crain M, Bingisser R. Antibiotic treatment of exacerbations of COPD: a randomised, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19.
20. Krueger S, Ewig S, Kunde J, et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict short- and long-term survival in community-acquired pneumonia. Eur Respir J 2009; 34: Suppl. 53, 296s.
21. Krueger S, Ewig S, Kunde J, et al. Pro-vasopressin (copeptin) in patients with community-acquired pneumonia - influence of antibiotic pre-treatment; results from the German competence network CAPNETZ. Eur Respir J 2009; 34: Suppl. 53, 296s.
22. Bernasconi M, Christ-Crain M, Müller C, et al. MR-proANP predicts 2-year survival in patients admitted for acute exacerbation of COPD. Eur Respir J 2009; 34: Suppl. 53, 748s-749s.
23. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471. (Pubitemid 34879333)
24. Desai H, Johnson A, Murphy T, et al. Mechanisms of persistence of Streptococcus pneumoniae following treatment of acute exacerbation of chronic bronchitis. Eur Respir J 2009; 34: Suppl. 53, 749s.
25. Marín-Tapia A, García-Aymerich J, Monsó E, et al. Effects of colonisation by Haemophilus influenzae in COPD stable patients. Eur Respir J 2009; 34: Suppl. 53, 749s-750s.
26. Murphy TF, Brauer AL, Schiffmacher T, et al. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 266-272.
27. Soler N, Agustí C, Angrill J, et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62: 29-35. (Pubitemid 46101763)
28. Nesterovich S, Bukreeva E. Peculiarities of brush-biopsies of bronchial mucosa at different aetiology of COPD exacerbations. Eur Respir J 2009; 34: Suppl. 53, 412s.
29. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-1121. (Pubitemid 43726892)
30. Biselli R, Mariotti S, Sargentini V, et al. Detection of IL-2 in addition to IFN-γ discriminates active tuberculosis patients, latently infected individuals and controls. Clin Microbiol Infect 2009; [Epub ahead of print PMID: 19886902].
31. Goletti D, Butera O, Vanini V, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 2010; 36: 135-142.
32. Ruhwald M, Bodmer T, Maier C, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008; 32: 1607-1615.
33. Jafari C, Thijsen S, Sotgiu G, et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis. A Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med 2009; 180: 666-673.
34. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
35. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-1189.
36. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
37. Sotgiu G, Sorete-Arbore A, Kliimann K, et al. Social determinants of MDR-TB in Europe: a multi-centre TBNET study. Eur Respir J 2009; 34: Suppl. 53, 786s.
38. Prasad BNBM, Rai SP, Falleiro JJ, et al. Prevalence and treatment outcome of drug resistant pulmonary tuberculosis in HIV negative cases - experience from a tuberculosis treatment center in India. Eur Respir J 2009; 34: Suppl. 53, 786s-787s.
39. Saygi A, Sungun F, Ekinci T, et al. Treatment outcome in multidrug resistant tuberculosis cases at our clinic between 1996-2008. Eur Respir J 2009; 34: Suppl. 53, 787s.
40. Legaspi MV. A two-year post-treatment follow-up of multi-drug resistant tuberculosis cases who completed a programmatic MDR-TB management at the lung center of the Philippines: a preliminary report. Eur Respir J 2009; 34: Suppl. 53, 787s.
41. Dheda K, Shean K, Badri M. Extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 2390.
42. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
43. Lovacheva O, Sivokozov I, Bagdasaryan T, et al. Local artificial atelectasis in treatment of end-stage XDR cavitary tuberculosis. Eur Respir J 2009; 34: Suppl. 53, 787s.
44. Andrejak C, Thomsen V, Johansen I, et al. The prognosis of patients colonized and infected with pulmonary nontuberculous mycobacteria in Denmark, 1997-2007: a nationwide population-based study. Eur Respir J 2009; 34: Suppl. 53, 435s.
45. Kobashi Y, Mouri K, Obase Y, et al. Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment. Eur Respir J 2009; 34: Suppl. 53, 435s.
46. Sim YS, Park HY, Kwon OJ, et al. Treatment outcome and prognostic factor in patients with Mycobacterium avium complex pulmonary disease. Eur Respir J 2009; 34: Suppl. 53, 436s.
47. Greinert H, Hörster R, Hoffmann C, et al. Successful treatment of rhodococcal pneumonia in advanced HIV-infection. Eur Respir J 2009; 34: Suppl. 53, 436s.
48. Shah A, Strickland N, Thomas C, et al. Characterisation of patients with multiple isolates of different species of non-tuberculous mycobacteria: a new phenomenon? Eur Respir J 2009; 34: Suppl. 53, 435s.
49. Khalilzadeh S, Baghaie N, Bloorsaz MR, et al. Bacteriological evaluation for diagnosis of tuberculosis in children. Eur Respir J 2009; 34: Suppl. 53, 438s.
50. Brinkmann F, Schwerk N, Gappa M, et al. Psoas abscesses in a child with multidrug resistant tuberculosis: is surgical drainage indicated? Eur Respir J 2009; 34: Suppl. 53, 440s.
51. Dobrota L, Neamtu M-L, Neamtu B, et al. P2492 chronic meningitis: a rare form of onset of tuberculosis infection in infants. Eur Respir J 2009; 34: Suppl. 53, 440s.
52. Pavlov N, Dragisic-Ivulic S, Pavlov V. Epidemiologic trends in children with tuberculosis (1999-2009). Eur Respir J 2009; 34: Suppl. 53, 439s-440s.
53. Eker B, Welling J, Greinert U, et al. Mycobacterium tilburgii infection in an HIV-seropositive host. Eur Respir J 2009; 34: Suppl. 53, 575s.
54. 2 in AIDS related severe Mycobacterium sherisii infection with acute respiratory distress syndrome (ARDS). Eur Respir J 2009; 34: Suppl. 53, 575s.
55. Leidl L, Mayanja-Kizza H, Sotgiu G, et al. Relationship of interferon-gamma release assay results and tuberculin skin test results to numbers of circulating CD4 T-cells in HIV infection. Eur Respir J 2009; 34: Suppl. 53, 573s.
56. Diez N, Latorre I, Giner E, et al. IFN-γ T cell response in the diagnosis of latent tuberculosis infection in children with a positive tuberculin skin test. Eur Respir J 2009; 34: Suppl. 53, 65s.
57. Losi M, Corona GL, Del Giovane C, et al. Using QuantiFERON-TB gold in-tube in contact tracing procedures. Eur Respir J 2009; 34: Suppl. 53, 66s.
58. Strassburg A, Guenther G, Sahly H, et al. Negative predictive value of serum-procalcitonin (PCT) for active pulmonary tuberculosis (pTB). Eur Respir J 2009; 34: Suppl. 53, 284s.